Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization by Hernández Tiedra, Sonia et al.
Autophagy
ISSN: 1554-8627 (Print) 1554-8635 (Online) Journal homepage: http://www.tandfonline.com/loi/kaup20
Dihydroceramide accumulation mediates cytotoxic
autophagy of cancer cells via autolysosome
destabilization
Sonia Hernández-Tiedra, Gemma Fabriàs, David Dávila, Íñigo J. Salanueva,
Josefina Casas, L. Ruth Montes, Zuriñe Antón, Elena García-Taboada, María
Salazar-Roa, Mar Lorente, Jesper Nylandsted, Jane Armstrong, Israel López-
Valero, Christopher S. McKee, Ana Serrano-Puebla, Roberto García-López,
José González-Martínez, José L. Abad, Kentaro Hanada, Patricia Boya,
Félix Goñi, Manuel Guzmán, Penny Lovat, Marja Jäättelä, Alicia Alonso &
Guillermo Velasco
To cite this article: Sonia Hernández-Tiedra, Gemma Fabriàs, David Dávila, Íñigo J. Salanueva,
Josefina Casas, L. Ruth Montes, Zuriñe Antón, Elena García-Taboada, María Salazar-
Roa, Mar Lorente, Jesper Nylandsted, Jane Armstrong, Israel López-Valero, Christopher S.
McKee, Ana Serrano-Puebla, Roberto García-López, José González-Martínez, José L. Abad,
Kentaro Hanada, Patricia Boya, Félix Goñi, Manuel Guzmán, Penny Lovat, Marja Jäättelä,
Alicia Alonso & Guillermo Velasco (2016) Dihydroceramide accumulation mediates cytotoxic
autophagy of cancer cells via autolysosome destabilization, Autophagy, 12:11, 2213-2229, DOI:
10.1080/15548627.2016.1213927
To link to this article:  https://doi.org/10.1080/15548627.2016.1213927
© 2016 The Author(s). Published with
license by Taylor & Francis.© Sonia
Hernández-Tiedra, Gemma Fabrias, David
Dávila, Íñigo J. Salanueva, Josefina Casas, L.
Ruth Montes, Zuriñe Antón, Elena Garcıa-
Taboada, María Salazar-Roa, Mar Lorente,
Jesper Nylandsted, Jane Armstrong, Israel
López-Valero, Christopher S. McKee, Ana
Serrano-Puebla, Roberto García-López, José
González-Martínez, José L. Abad, Kentaro
Hanada, Patricia Boya, Felix Goñi, Manuel
Guzman, Penny Lovat, Marja Jäättelä, Alicia
Alonso, and Guillermo Velasco.
View supplementary material 
Published online: 16 Sep 2016.
Submit your article to this journal 
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=kaup20
Article views: 3519
View related articles 
View Crossmark data
Citing articles: 10 View citing articles 
TRANSLATIONAL RESEARCH PAPER
Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via
autolysosome destabilization
Sonia Hernandez-Tiedraa,b, Gemma Fabriasc, David Davilaa,b,I~nigo J. Salanuevaa, Joseﬁna Casasc, L. Ruth Montesd,
Zuri~ne Antond, Elena Garcıa-Taboadaa, Marıa Salazar-Roaa, Mar Lorentea,b, Jesper Nylandstede, Jane Armstrongf,g,
Israel Lopez-Valeroa,b, Christopher S. McKeef, Ana Serrano-Pueblaa,h, Roberto Garcıa-Lopeza, Jose Gonzalez-Martıneza,b,
Jose L. Abadc, Kentaro Hanadai, Patricia Boyah, Felix Go~nid, Manuel Guzmana,j, Penny Lovatf, Marja J€a€attel€ae,
Alicia Alonsod, and Guillermo Velascoa,b
aDepartment of Biochemistry and Molecular Biology I, School of Biology, Complutense University, Madrid, Spain; bInstituto de Investigaciones
Sanitarias San Carlos (IdISSC), Madrid, Spain; cResearch Unit on BioActive Molecules (RUBAM), Departments of Biomedicinal Chemistry, Institute for
Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain; dBioﬁsika Institute (UPV/EHU, CSIC), and Departamento de Bioquımica, Universidad del
Paıs Vasco, Barrio Sarriena s/n, Leioa, Spain; eUnit of Cell Death and Metabolism, Center for Autophagy, Recycling and Disease, Danish Cancer Society
Research Center (DCRC), Copenhagen, Denmark; fDermatological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne,
UK; gFaculty of Applied Sciences, University of Sunderland, Sunderland, UK; hDepartament of Cellular and Molecular Biology, Centro de Investigaciones
Biologicas, CSIC, Madrid, Spain; iDepartment of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan;
jCentro de Investigacion Biomedica en Red Sobre Enfermedades Neurodegenerativas, Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain,
Instituto Universitario de Investigacion Neuroquımica, Complutense University, Madrid, Spain
ARTICLE HISTORY
Received 21 October 2015
Revised 21 June 2016
Accepted 13 July 2016
ABSTRACT
Autophagy is considered primarily a cell survival process, although it can also lead to cell death. However,
the factors that dictate the shift between these 2 opposite outcomes remain largely unknown. In this
work, we used D9-tetrahydrocannabinol (THC, the main active component of marijuana, a compound that
triggers autophagy-mediated cancer cell death) and nutrient deprivation (an autophagic stimulus that
triggers cytoprotective autophagy) to investigate the precise molecular mechanisms responsible for the
activation of cytotoxic autophagy in cancer cells. By using a wide array of experimental approaches we
show that THC (but not nutrient deprivation) increases the dihydroceramide:ceramide ratio in the
endoplasmic reticulum of glioma cells, and this alteration is directed to autophagosomes and
autolysosomes to promote lysosomal membrane permeabilization, cathepsin release and the subsequent
activation of apoptotic cell death. These ﬁndings pave the way to clarify the regulatory mechanisms that
determine the selective activation of autophagy-mediated cancer cell death.
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Introduction
Macroautophagy, hereafter named autophagy, is a highly con-
served cellular process in which cytoplasmic materials, including
organelles, are sequestered into double-membrane compart-
ments, phagophores, that mature into autophagosomes; the
cargo is subsequently delivered to lysosomes for degradation
and recycling.1-3 In many cellular settings, triggering of auto-
phagy relies on the inhibition of MTORC1 (mechanistic target
of rapamycin [serine/threonine kinase] complex 1), an event
that promotes the activation (de-inhibition) of several ATG
(autophagy-related) proteins involved in the initial phase of
phagophore formation.1-3 The membrane source from which
autophagosomes are derived is still debatable, as it has been pro-
posed that it could be derived either from de novo synthesized
lipids or generated by vesicle budding from the endoplasmic
reticulum (ER), Golgi apparatus or endosomes,4,5 or the plasma
membrane.6 In particular, an ER-derived structure termed the
omegasome has been proposed as an origin of the phagophore
membrane.5,7 Enlargement of this compartment to form the
autophagosome requires the participation of 2 ubiquitin-like
conjugation systems, one involving the conjugation of ATG12
(autophagy-related 12) to ATG5 (autophagy-related 5), and the
other of phosphatidylethanolamine to MAP1LC3/LC3 (microtu-
bule-associated protein 1 light chain 3).2 The ﬁnal outcome of
the activation of the autophagy program is highly dependent on
the cellular context and the strength and duration of the stress-
inducing signals. Thus, autophagy plays an important role in
cellular homeostasis and is considered primarily a cell-survival
mechanism, for example in situations of nutrient deprivation.8-11
However, stimulation of autophagy can also have a cytotoxic
effect. For example, several anticancer agents activate auto-
phagy-associated cell death.8-10,12 However, the molecular
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mechanisms that determine the outcome of autophagy activa-
tion for the survival or death of cancer cells remain to be
clariﬁed.
D9-Tetrahydrocannabinol (THC), the main active compo-
nent of Cannabis sativa,13,14 exerts a wide variety of biological
effects by mimicking endogenous substances—the endocanna-
binoids anandamide15 and 2-arachidonoylglycerol (2-AG)16,17
that engage speciﬁc cell-surface G protein-coupled cannabinoid
receptors.14 So far, 2 major cannabinoid-speciﬁc receptors,
CNR1/CB1 (cannabinoid receptor 1 [brain]) and CNR2/CB2
(cannabinoid receptor 2 [macrophage]), have been cloned and
characterized from mammalian tissues.18,19 Cannabinoid
administration curbs the growth of several genetic and xeno-
graft models of cancer in rats and mice, and therefore these
compounds are considered a novel family of potential antican-
cer agents.20 The mechanism of cannabinoid anticancer action
relies, at least largely, on the ability of these agents to stimulate
autophagy-mediated cancer cell death.20 Thus, THC binds can-
nabinoid receptors, which leads to the stimulation of de novo
sphingolipid synthesis and the subsequent activation of an
endoplasmic reticulum (ER) stress-related signaling route that
involves the upregulation of the transcriptional co-activator
NUPR1/p8 (nuclear protein 1, transcriptional regulator) and
its effector TRIB3 (tribbles pseudokinase 3).20-23 The stimula-
tion of this pathway promotes in turn autophagy via
TRIB3-mediated inhibition of the AKT (thymoma viral proto-
oncogene)-MTORC1 axis, which is indispensable for the pro-
apoptotic and antitumoral action of cannabinoids.24,25
In this study, we have investigated the molecular mechanism
underlying the activation of autophagy-mediated cancer cell death
by comparing the effects of THC treatment and nutrient depriva-
tion, 2 autophagic stimuli that produce opposite effects on the reg-
ulation of cancer cell survival/death. Using this experimental
model, we found that treatment with THC—but not exposure to
nutrient deprivation—leads to an alteration of the balance
between different molecular species of ceramides and dihydrocer-
amides in themicrosomal (endoplasmic reticulum-enriched) frac-
tion of cancer cells. Moreover, our ﬁndings support the hypothesis
that suchmodiﬁcation can be transmitted to autophagosomes and
autolysosomes, where it can promote the permeabilization of the
organellar membrane, the release of cathepsins to the cytoplasm
and the subsequent activation of apoptotic cell death.
Results
THC-induced, but not nutrient deprivation-induced,
autophagy relies on the stimulation of sphingolipid
biosynthesis
As a ﬁrst approach to investigate the molecular mechanisms
responsible for the activation of autophagy-mediated cancer
cell death we analyzed the effect of 2 different stimuli, namely
nutrient deprivation and THC treatment, that trigger cytopro-
tective and cytotoxic autophagy, respectively. We found that
genetic inhibition of the autophagy essential gene ATG5 in
both U87MG cells and oncogene-transformed mouse embry-
onic ﬁbroblasts (MEFs) prevented THC-induced cell death
while it further diminished the nutrient deprivation-induced
decrease in cell viability (Fig. 1A and Fig. S1A), thus supporting
the notion that stimulation of autophagy may play a dual role
in the regulation of cancer cell survival.
After conﬁrming that incubation with EBSS and treatment
with THC led to an increase in the accumulation of
MAP1LC3B-positive dots in U87MG cells (Fig. S1B) we ana-
lyzed the ability of these 2 stimuli to enhance the autophagic ﬂux
in U87MG cells. To this aim, we performed the treatments in the
presence or the absence of the lysosomal proteases inhibitors
E64d and pepstatin A (C inh); upon stimulation of dynamic
autophagy and in the presence of these inhibitors there is a
blockade of the autophagic ﬂux and therefore an enhanced accu-
mulation of proteins present in the autophagosomes, and speciﬁ-
cally of the lipidated and autophagosome-associated form of
MAP1LC3, MAP1LC3-II. Of note, incubation with EBSS
induced only an early and transient increase in the autophagic
ﬂux (EBSS led to MAP1LC3B-II accumulation, an event that was
enhanced in the presence of E64d C pepstatin A; Fig. 1A lower
panel, Fig. 1B and Fig. S1C) whereas stimulation of the autopha-
gic ﬂux by THC occurred at longer times and was sustained for
several hours (Fig. 1A lower panel, Fig. 1B and Fig. S1C).
Previous reports by our group show that the stimulation of
sphingolipid biosynthesis by THC is involved in the induction
of autophagy-mediated cancer cell death.20,21,24,26,27 In agree-
ment with these observations, we found here that THC upregu-
lates mRNA levels of different enzymes involved in
sphingolipid synthesis de novo, an effect that was not observed
when cells were exposed to EBSS (Fig. 1C). Likewise, pharma-
cological blockade (by using ISP-1) of SPT (serine palmitoyl-
transferase), the enzyme that catalyzes the ﬁrst step of
sphingolipid biosynthesis, prevented THC-, but not nutrient
deprivation-induced autophagy (Fig. 1D). In addition, we con-
ﬁrmed that, in agreement with previous observations,22,24,27
incubation with ISP-1 inhibited THC-evoked cell death
(Fig. S1D). Collectively, these results suggest that a general
increase in de novo-synthesized sphingolipids might be a differ-
ential factor in the activation of cytotoxic autophagy by THC.
THC, but not nutrient deprivation, enhances sphingolipid
synthesis de novo and dihydroceramide accumulation
The initial steps of sphingolipid biosynthesis occur at the ER,28
where ceramides are synthesized (Fig. 2A). Therefore, as a ﬁrst
approach to investigate the effect of THC and nutrient depriva-
tion on sphingolipid metabolism, we analyzed the sphingolipid
composition of the microsomal fraction of U87MG cells sub-
jected to either stimulus. As shown in Fig. 2B, THC—but not
incubation with EBSS—increased ceramide levels in the micro-
somal fraction of U87MG cells. We also found that THC but
not EBSS enhanced the levels of dihydroceramides to a higher
extent than those of ceramides (Fig. 2B and Fig. 2C). DEGS1/
dihydroceramide desaturase (delta[4]-desaturase, sphingolipid
1) catalyzes the insertion of a 4,5-trans double bond in the
sphingoid backbone of dihydroceramides to generate ceramides
(see Fig. 2A).28 Speciﬁcally, treatment with THC produced a
2.8-, 2.9- and 4.5-fold increase in the levels of C16, C24 and
C24:1 dihydroceramides, respectively, and a 1.3- and 1.2-fold
increase in the levels of C24 and C24:1 ceramides, respectively
(Fig. S2). It should be noted that ceramide levels were 6- to 10-
fold higher than those of dihydroceramides in vehicle-treated
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cells (Fig. 2C and Table S1). Thus, the observed increase in
dihydroceramides levels triggered by THC led to a striking
modiﬁcation of the ceramide:dihydroceramide ratio in the
microsomal fraction of U87MG cells (Fig. 2D).
THC, but not nutrient deprivation, inhibits sphingolipid
transport from the ER to the Golgi
Once synthesized in the ER, ceramides can be delivered via
vesicular transport or through the ceramide transporter protein
COL4A3BP/CERT (collagen, type IV, a 3 [Goodpasture anti-
gen] binding protein)29 to the Golgi apparatus, where the
synthesis of sphingomyelin and complex glycosphingolipids
takes place.28 One way to approach the analysis of this process is
to follow the subcellular distribution of ﬂuorescent dye-conju-
gated ceramides, for example BODIPY C5 ceramide. Thus,
when added to cells, BODIPY C5 ceramide is endocytosed and
rapidly transported to the Golgi. We therefore monitored BOD-
IPY C5 ceramide distribution to analyze the effect of THC on
ceramide transport from the ER to the Golgi. As shown in
Fig. 3A, BODIPY C5 ceramide was located in perinuclear struc-
tures resembling the Golgi apparatus in U87MG cells treated
with vehicle or subjected to nutrient deprivation. In contrast,
THC treatment induced a particulate distribution of BODIPY
Figure 1. THC, but not nutrient deprivation, -induced autophagy relies on the stimulation of sphingolipid biosynthesis. (A) Upper panel: Effect of THC (4 mM, 18 h) and
incubation with EBSS (18 h) on the number of U87MG cells stably transfected with control (shC) or ATG5-selective (shATG5) shRNAs as estimated by the MTT test (n D 4;
mean § s.d; , P < 0.01 from THC-treated or EBSS-incubated U87 shC cells). Lower panel: Effect of THC (4 mM) and incubation with EBSS on the induction of autophagy
(as determined by MAP1LC3B-II lipidation in the presence of E64d, 10 mM; and pepstatin A, 10 mg/ml [Cinh]) of U87 cells stably transfected with control (U87 shC) or
ATG5-selective (shATG5) shRNAs (n D 3, a representative experiment is shown). ATG5 mRNA levels (as determined by real-time quantitative PCR) were reduced by
85 § 3% on U87shATG5 cells when compared with U87shC cells; (n D 4). Values in the bottom of the western blots correspond to the fold change in the MAP1LC3B-II to
TUBA1A ratio relative to shC U87MG cells at the initial time point of the treatments. Nd, nondetectable. (B) Effect of THC (4 mM, 1 h, 3 h and 6 h) and incubation with EBSS
(i.e., nutrient deprivation, 1, 3 and 6 h) on the induction of autophagy (as determined by MAP1LC3B-II lipidation in the presence of E64d, 10 mM; and pepstatin A, 10 mg/
ml [Cinh]) of U87MG cells (n D 3, a representative experiment is shown). (C) Effect of THC (4 mM; 3 h) on the mRNA levels (as determined by quantitative real-time PCR)
of different enzymes involved in sphingolipid biosynthesis (CERS2; CERS5; CERS6 (ceramide synthase 2, 5 and 6), DEGS1/dihydroceramide desaturase (delta[4]-desaturase,
sphingolipid 1) and SPTLC1 (serine palmitoyltransferase long chain base subunit 1) of U87MG cells (n D 5; , P < 0.05; , P < 0.01 from Veh-treated cells). (D) Effect of
THC (4 mM), ISP-1 (5 mM) and incubation with EBSS on autophagy (18 h) (as determined by MAP1LC3B immunostaining). Note that incubation with ISP-1 prevents THC
but not starvation-induced autophagy of U87MG cells. Values correspond to the percentage of cells with MAP1LC3B dots relative to the total cell number of cells § s.d;
nD 3. , P < 0.05; , P < 0.01 from Veh-treated cells and #, P < 0.05 from THC- and EBSS-treated cells. Bar: 20 mm.
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C5 ceramide (Fig. 3A). Moreover, this probe colocalized with the
ER marker PDIA (protein disulﬁde isomerase associated)
(Fig. 3A, right panel) and showed a striking decrease in the
colocalization with the Golgi marker TGOLN2/TGN46 (trans-
golgi network protein 2) as compared with vehicle-treated cells
(Fig. S3A), suggesting that THC, but not nutrient deprivation,
Figure 2. THC, but not nutrient deprivation, stimulates sphingolipid synthesis de novo, enhances dihydroceramide levels and modiﬁes the ceramide:dihydroceramide
ratio in the microsomal fraction of U87MG cells. (A) Scheme depicting the pathway of sphingolipid synthesis de novo. SPT (serine palmitoyltransferase) catalyzes the con-
densation of serine and palmitoyl-CoA to produce 3-ketosphinganine. KDSR (3-ketodihydrosphingosine reductase) catalyzes the reduction of 3-ketosphinganine to dihy-
drosphingosine (sphinganine). The next reaction is catalyzed by CERS1 to CERS6 (each isoform of this enzyme has selectivity for fatty acyl-CoAs with different chain
length). CERSs convert dihydrosphingosine into the different molecular species of dihydroceramides, which are subsequently transformed into ceramides by the insertion
of a 4, 5-trans double bond catalyzed by the enzymes DEGS1 and DEGS2. ISP-1 and GT11 are pharmacological inhibitors of SPT and DEGS, respectively (B) Effect of THC
treatment (6 mM, 6 h) and nutrient deprivation (EBSS; 6 h) on the levels of total ceramides and dihydroceramides found in the microsomal fraction of U87MG cells. Data
are expressed as the mean fold change in the levels of total dihydroceramides and total ceramides § s.d. relative to vehicle-treated cells (n D 4; , P< 0.001 and
, P < 0.05 from vehicle-treated cells). (C) Effect of THC treatment (6 mM, 6 h) on the levels of the different molecular species of dihydroceramides (left panel) and ceram-
ides (right panel) found in the microsomal fraction of U87MG cells. Data are expressed in pmol of sphingolipid per mg of protein (mean § s.d; n D 5; , P < 0.05 from
vehicle-treated cells). S indicates the total content in ceramide or dihydroceramide (expressed as the sum of the individual molecular species of ceramide or dihydrocera-
mide detected in these analyses) (D) Effect of THC treatment (6 mM; 6 h) on the ceramide:dihydroceramide ratio § s.d. found in the microsomal fraction of U87MG cells.
(n D 5; , P < 0.001; , P < 0.01; and , P < 0.05 from vehicle-treated cells). Note that THC treatment produces an increase in the levels of different species of dihydro-
ceramides, which leads to a change in the ratio of both types of sphingolipids in the microsomal fraction of U87MG cells.
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affects the intracellular trafﬁcking of sphingolipids by favoring
the accumulation of sphingolipids in the ER.
In agreement with this idea, analysis of COL4A3BP distribu-
tion revealed that this protein was located in the Golgi apparatus
of vehicle- or EBSS-treated cells, whereas it exhibited a particu-
late distribution upon challenge with THC (Fig. 3B). We also
found that treatment with THC enhanced COL4A3BP phos-
phorylation (Fig. S3B), an event that promotes a conformational
change in this protein that inhibits its ability to transport cer-
amide from the ER to the Golgi.30-32 Surprisingly, immunostain-
ing analyses revealed that THC triggered the colocalization of
COL4A3BP with MAP1LC3B-positive dots (Fig. 3C). Moreover,
electron microscopy analysis of cells that had been treated with
THC showed that COL4A3BP was present in the membrane of
vesicles with the morphology of phagophores/autophagosomes
(Fig. 3D, and Fig. S3C). Furthermore, the colocalization of
COL4A3BP and MAP1LC3B in response to THC was strongly
reduced when Ser132—the residue that is primarily phosphory-
lated to promote COL4A3BP inactivation—was mutated to Ala
(Fig. S3D and Fig. S3E), suggesting that THC promotes the
phosphorylation and inactivation of COL4A3BP and its localiza-
tion in phagophores and/or autophagosomes.
Figure 3. THC, but not nutrient deprivation, inhibits sphingolipid transport from the ER to the Golgi. (A) Effect of THC (4 mM) and EBSS on BODIPY C5 ceramide (BODIPY-
Cer) distribution of U87MG cells (cells were incubated at 4C in the presence of BODIPY C5 ceramide, treated with THC or EBSS and incubated at 37C for the indicated
time) (n D 4). Note that THC, but not nutrient deprivation, produces an accumulation of BODIPY C5 ceramide in vesicles. Right panel: Effect of THC (4 mM, 2 h) on the
colocalization of BODIPY C5 ceramide and the ER marker PDIA (protein disulﬁde isomerase family A member) (n D 4). Bar: 20 mm. (B) Effect of THC (4 mM, 18 h) and EBSS
on the subcellular distribution of the ceramide transporter protein COL4A3BP/CERT (n D 4). A representative experiment is shown. Values in the lower right corner of
each photomicrograph correspond to the percentage of cells § s.d. exhibiting a vesicular distribution of COL4A3BP. Note that COL4A3BP colocalizes with the Golgi
marker GOLGA2/GM130 in EBSS but not in THC-treated cells (upper panels) and that both EBSS and THC trigger autophagy (as determined by the presence of
MAP1LC3B-positive dots; lower panels) under these experimental conditions. Bar: 20 mm. (C) Effect of THC (4 mM, 18 h) on the subcellular distribution COL4A3BP-GFP in
MAP1LC3B-positive vesicles. Bar: 20 mm. Right panels correspond to a higher magniﬁcation image of the cell region marked with a white square in the middle panel. The
bottom right panel shows the colocalization of COL4A3BP-GFP and MAP1LC3B (white spots) in that speciﬁc cell region. (D) Immunodectection of COL4A3BP by electron
microscopy. Note the presence of COL4A3BP (black spots, marked with black triangles) in double-membrane vesicles present in THC-treated cells (right panel). Bar:
500 nm. Representative electron microscopy images of COL4A3BP immunodetection in vehicle (Veh)- and THC-treated cells are shown in Figure S3C.
AUTOPHAGY 2217
To investigate whether COL4A3BP associates with omega-
somes we analyzed COL4A3BP localization in ATG5-deﬁcient
cells. Note that ATG5 deﬁciency impairs autophagosome elon-
gation, but not the formation of omegasomes33 that can still be
detected in these cells when subjected to autophagic stimuli. In
line with this idea, treatment with THC promoted the recruit-
ment of COL4A3BP to ring-shaped structures resembling those
previously described as characteristic of omegasomes
(Fig. S4A). Moreover, THC promoted the colocalization of
COL4A3BP with ZFYVE1/DFCP1 (zinc ﬁnger, FYVE domain
containing 1) (Fig. S4B) and WIPI1 (WD repeat domain, phos-
phoinositide interacting 1) (Fig. S4C), 2 proteins located in
these structures.3,33 Taken together, these observations support
the conclusion that THC, but not nutrient deprivation,
enhances sphingolipid biosynthesis and inhibits the transport
of sphingolipids from the ER to the Golgi.
THC, but not nutrient deprivation, modiﬁes the
sphingolipid composition of autophagosomes
Next we asked whether the changes induced by THC on the ER
sphingolipid composition could lead to changes in the sphingo-
lipid composition of autophagosomes. To investigate this possi-
bility, we performed subcellular fractionation experiments to
analyze the characteristics of the autophagosomal fraction of
U87MG cells treated with THC or subjected to nutrient depri-
vation. As shown in Fig. 4A and Fig. S5A, the autophagosome-
enriched fraction derived from cells that had been treated with
Figure 4. THC, but not nutrient deprivation, decreases the ceramide:dihydroceramide ratio in an autophagosome-enriched fraction. (A) Characterization of the presence
of the autophagy marker MAP1LC3B-II and the lysosomal marker LAMP1 in fractions obtained from U87MG cells incubated for 6 h with EBSS or THC (6 mM) and subjected
to subcellular fractionation in an OptiPrep gradient. Note that MAP1LC3B-II appears in fractions of higher density in samples derived from THC-treated cells than in those
derived from cells incubated with EBSS, (n D 2). (B) Analysis of the molecular species of ceramides and dihydroceramides present in the MAP1LC3B-II-enriched fraction
(derived from cells treated with THC or incubated with EBSS) shown in (A). Data correspond to the ceramide:dihydroceramide ratio (upper panel) and the amount of each
sphingolipid species (lower panel) in one representative experiment (n D 2). (C) Generation of ceramide rigid domains in C16 dihydroceramide-containing GUVs. Upper
panel: Rigid, dihydroceramide-enriched domains (ﬂower-like dark areas) in bilayers containing 80 mol % sn-1-palmitoyl-2-oleoyl phosphatidylcholine (POPC, a ﬂuid phos-
pholipid) and 20 mol % C16 dihydroceramide. Lower panel: a control experiment with a C12 dihydroceramide that does not give rise to domains under these conditions.
Bars: 10 mm. (D) Release of vesicular aqueous contents induced by ceramides. Effect of the different proportions of C16 ceramide:C16 dihydroceramide generated by the
action of sphingomyelinase in LUVs composed of the following: dhSM:PC:Ch (30:67:3; red line); SM:dhSM:PC:Ch (20:10:67:3; magenta line); SM:PC:Ch (30:67:3; blue line);
and SM:dhSM:PC:Ch (26:4:67:3; green line). A representative example of 3 closely similar experiments is shown. SM, sphingomyelin; dhSM, dihydrosphingomyelin; PC,
phosphatidylcholine; Ch, cholesterol.
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THC exhibited a higher density (corresponding to a higher
fraction) than that from cells treated with EBSS. Moreover,
analysis of the sphingolipid composition of these fractions
revealed that dihydroceramide levels were higher (and there-
fore the ceramide:dihydroceramide ratios were lower) in the
autophagosome-enriched fraction from THC-treated cells than
in that obtained from cells exposed to EBSS (Fig. 4B).
Dihydroceramides destabilize biological membranes
To investigate the potential relevance of the changes observed
in the sphingolipid composition of autophagosomes and auto-
lysosomes, and speciﬁcally of the increased dihydroceramides
levels in THC-treated cells, we undertook a series of experi-
ments to analyze the role of these lipids in model vesicles. As
THC produced a larger increase in the levels of C16 dihydro-
ceramide (C16-dhCer) than in those of other dihydroceramides
(Fig. 2C and Fig. S8A), we selected this molecule to carry out
these studies. Experiments performed with giant unilamellar
vesicles (GUVs) indicated that C16-dhCer gives rise to ﬂower-
shaped, rigid domains (characteristic of inhomogeneous mem-
brane regions)34 in these vesicles (Fig. 4C). A control experi-
ment with a shorter chain (C12) dihydroceramide failed to
cause lateral domain formation, supporting the notion that (as
occurs with ceramides)34 under these conditions only long-
chain dihydroceramides give rise to rigid domains.
Likewise, calorimetric phase transition experiments showed
that C16-dhCer (prepared in a mixture with egg phosphatidyl-
choline) exhibited a more complex transition, (extending over
higher temperatures) than C16 ceramide (C16-Cer) (Fig. S5B);
i.e. the membrane rigidifying effect of C16-dhCer is higher
than that of C16-Cer. These observations suggest that an
enhanced proportion of dihydroceramide facilitates the forma-
tion of rigid domains in biological membranes. We therefore
analyzed whether these dihydroceramide-enriched domains
can contribute to membrane destabilization. To this aim we
used large unilamellar vesicles (LUVs) loaded with a water-sol-
uble ﬂuorescent dye. Changes in membrane stability of these
vesicles can be determined by measuring the release of the
vesicle’s aqueous contents. Thus, addition of bacterial sphingo-
myelinase to LUVs containing different proportions of C16
sphingomyelin and C16 dihydrosphingomyelin led to the for-
mation of ceramide and/or dihydroceramide in the membrane
of these vesicles, allowing for the analysis of the effect of acute
increases in the level of ceramide and/or dihydroceramide on
membrane stability. As shown in Fig. S5C, the release of the
vesicle’s aqueous contents induced by dihydroceramide was
larger and faster than that induced by ceramide.
Next, we prepared vesicles with lipid compositions that
mimicked that of the microsomal and autophagosome-
enriched fraction of cells treated with THC or EBSS (containing
sphingomyelin and dihydrosphingomyelin in the same propor-
tion as those of ceramides and dihydroceramides after treat-
ment with THC or EBSS). Addition of sphingomyelinase to
these membranes showed that a higher proportion of dihydro-
ceramides resulted in a more rapid and extensive release of
aqueous contents from these vesicles (Fig. 4D). Taken together,
these observations support the notion that a decrease in the cer-
amide:dihydroceramide ratio (similar to that induced by THC
in the microsomal and autophagosome-enriched fraction of
live cells) leads to the formation of speciﬁc membrane domains
and to a subsequent destabilization (increased permeability) of
the membrane.
THC promotes sphingolipid- and autophagy-dependent
lysosomal membrane permeabilization
Lysosomal membrane permeabilization (LMP) produces cell
death as a consequence of the release of lysosomal proteases to
the cytoplasm.35,36 Therefore, considering the above-described
membrane permeabilizing effect of dihydroceramide, we inves-
tigated whether the cell death promoting activity of THC relies
on a sphingolipid-dependent induction of LMP. In line with
this idea, treatment with THC produced an increase in cyto-
solic CTSB (cathepsin B) and CTSL (cathepsin L) activity and
caused the appearance of CTSB in the cytosol of both U87MG
cells and the melanoma cell line SK-MEL-28, these events being
prevented by the pharmacological inhibition of sphingolipid
synthesis de novo (Fig. 5A, Fig. 5B and Fig. S6A). Moreover, we
found that THC-induced CTSB release was abrogated in
U87MG and SK-MEL-28 cells and in oncogene-transformed
MEFs in which autophagy had been genetically inhibited
(Fig. 5C, Fig. 5D, Fig. S6B, Fig. S6C, Fig. S7A and Fig. S7B),
indicating that autophagy stimulation is required for THC-
induced LMP. Collectively these observations suggest that the
increase in the dihydroceramide autophagosomal content that
triggers THC leads to autolysosomal membrane destabilization,
LMP and cathepsin release.
LMP triggers the activation of the mitochondrial apoptotic
pathway although it can also lead to necrotic cell death.36-38 In
agreement with our previous ﬁndings showing that autophagy
is upstream of apoptosis in the mechanism of cannabinoid-
induced cell death,24 we found that treatment with THC
induced apoptosis and did not lead to a signiﬁcant increase in
necrotic cell death (Fig. S7D). Hence, we next tested whether
CYCS (cytochrome c, somatic) release from mitochondria (an
event that is closely associated with the activation of the intrin-
sic apoptotic pathway) was regulated by THC-induced LMP.
Supporting this hypothesis, THC treatment promoted mito-
chondrial CYCS release, an event which was prevented by the
pharmacological inhibition of sphingolipid biosynthesis and
CTSB activity (Fig. 5D and Fig. 5E, Fig. S6C and Fig. S6D).
Likewise, genetic inhibition of autophagy prevented THC-
induced CTSB and CYCS release (Fig. 5D and Fig. S6C). Fur-
thermore, pharmacological inhibition of cathepsins prevented
THC-induced cell death (Fig. 5F and Fig. S7C). Taken together,
these ﬁndings show that THC-induced autophagy promotes
LMP and the subsequent activation of the mitochondrial apo-
ptotic pathway in a sphingolipid biosynthesis- and autophagy-
dependent manner.
Pharmacological manipulation of the dihydroceramide
content activates autophagy-mediated cancer cell death
and inhibits tumor growth in vivo
To investigate the in vivo relevance of our observations we ana-
lyzed the effect of THC on the growth of U87MG cell-derived
subcutaneous tumor xenografts. Treatment with THC reduced
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tumor growth (Fig. 6A), which correlated with an increase in
the levels of C16 dihydroceramide and a decrease in the ratio
ceramide:dihydroceramide (Fig. 6B). Likewise, analysis of these
samples revealed that treatment with THC enhanced auto-
phagy (as determined by MAP1LC3B lipidation) (Fig. 6C);
increased the intensity of CTSB immunostaining (Fig. 6D); and
Figure 5. THC promotes lysosomal membrane permeabilization in a sphingolipid- and autophagy-dependent manner. (A) Effect of THC (4 mM) and ISP-1 (5mM) on CTSB
(cathepsin B) C CTSL (cathepsin L) cysteine protease activity in the cytosolic fraction of U87MG cells (16 h). Data are expressed as the mean fold increase in cytosolic
CTSB C CTSL cysteine protease activity § s.d. relative to vehicle-treated cells (n D 4; , P< 0.01 from vehicle-treated cells; and #, P < 0.05 from THC-treated cells). (B)
Effect of THC (4 mM) and ISP-1 (5 mM) on CTSB and LAMP2 (lysosomal-associated membrane protein 2) subcellular distribution (as determined by immunoﬂuorescence)
of SK-MEL28 metastatic melanoma cells (n D 3). Bar: 20 mm. Bottom panels correspond to higher magniﬁcation images of the cells marked with white squares in the
upper panels. Single and merged channels for these microphotographs are shown in Fig. S6A. (C) Effect of THC (18 h) on CTSB distribution in the cytosolic fraction of
Atg5C/C or atg5¡/¡ (autophagy-deﬁcient) HRASV12/T-large-transformed MEFs (n D 3). Western blots of a representative experiment are shown. NFKBIA/IkBa (NFKB
inhibitor a) is included as a control for the presence of cytosolic proteins in the cytosolic fraction. Values in the bottom of the western blots correspond to the mean fold
change in the mature CTSB to ACTB/b-actin ratio § s.e. relative to vehicle-treated Atg5C/C cells (n D 3; , P < 0.05 from vehicle-treated cells). Analysis of CTSB distribu-
tion in the membrane fraction is shown in Fig. S6B. (D) Effect of THC (4 mM, 16 h) on CTSB and CYCS (cytochrome c, somatic) distribution in the cytosolic fraction of shC
and shATG5 U87MG cells (nD 3; a representative western blot is shown). NFKBIA is included as a control of the presence of cytosolic proteins in the cytosolic fraction. Val-
ues in the bottom of the western blots correspond to the fold change in the mature CTSB to ACTB ratio§ s.e. and in the CYCS to ACTB ratio§ s.e., respectively, relative to
shC U87MG vehicle-treated cells (nD 3; , P < 0.05 from vehicle-treated cells; and #, P < 0.05 from THC-treated cells). Analysis of CTSB and CYCS distribution in the mem-
brane fraction is shown in Fig. S6C. (E) Effect of THC (4 mM), ISP-1 (5 mM) and CTSB inhibitor (10 mM) on CYCS distribution in the cytosolic fraction of U87MG cells (n D 2;
a representative western blot is shown). NFKBIA is included as a control of the presence of cytosolic proteins in the cytosolic fraction. Values in the bottom of the western
blot correspond to the fold change in the CYCS to ACTB (actin, b) ratio relative to U87MG vehicle-treated cells. Analysis of CYCS distribution in the membrane fraction is
shown in Fig. S6D. (F) Effect of THC (5 mM) and of the cysteine protease inhibitor E64d (10 mM) and the aspartic protease inhibitor pepstatin A (PA; 10 mg/ml) on the
number of U87MG cells (as estimated by the MTT test, 18 h) (n D 4; , P < 0.01; ##, P < 0.01).
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enhanced apoptosis (as determined by TUNEL) (Fig. 6E and
Fig. S8F). Taken together, these observations indicate that treat-
ment with THC activates the autophagy-mediated cell death
pathway in vivo.
Finally, we questioned whether manipulation of the dihy-
drosphingolipid content of glioma cells by other means might
also facilitate the stimulation of autophagy-mediated cell death.
To this aim we analyzed the effect of the DEGS1
pharmacological inhibitor GT11.39 As expected, GT11
enhanced dihydroceramide levels and decreased total ceramide
levels of U87MG cells (Fig. S8A). Likewise, incubation with this
inhibitor induced autophagy (Fig. S8B), CTSB C CTSL release
(Fig. S8C) and cell death (Fig. S8D), and enhanced the effect of
submaximal doses of THC (Fig. S8B, Fig. S8D and Fig. S8E).
Moreover, GT11 decreased the growth of U87MG cell-derived
subcutaneous tumor xenografts to a similar extent than THC
Figure 6. Pharmacological manipulation of the dihydroceramide content of cancer cells activates autophagy-mediated cell death in vivo and inhibits the growth of
U87MG cell-derived xenografts. (A) Effect of THC (15 mg/kg; peritumoral administration), GT11 (7.5 mg/kg, peritumoral administration) or THC and GT11 on the growth
of tumors generated by subcutaneous injection of U87MG cells. Data are expressed as mean fold increase § SEM relative to d 1 (n D 6 for each experimental condition;
, P< 0.01 or , P < 0.05 from vehicle-treated tumors; ##, P < 0.01 from THC-treated tumors and $, P < 0.05 from GT11-treated tumors). (B) Effect of THC (15 mg/kg),
GT11 (7.5 mg/kg) or THC and GT11 on the ceramide:dihydroceramide ratio of tumors generated with U87MG cells. (n D 3; , P < 0.01 or , P < 0.05 from vehicle-treated
tumors). (C) Effect of THC (15 mg/kg), GT11 (7,5 mg/kg) or THC and GT11 on autophagy (as determined by MAP1LC3B lipidation). Western blot corresponds to the analysis
of 2 different animals/tumors per experimental condition. (D) Effect of THC (15 mg/kg), GT11 (7.5 mg/kg) or THC and GT11 on CTSB immunostaining. Values in the lower
left corner correspond to the CTSB-stained area relative to the number of nuclei in each ﬁeld; these correspond to 10 ﬁelds of 3 different tumors for each condition and
are expressed as the mean fold change § s.d. , P < 0.01 from vehicle-treated tumors; ##, P < 0.01 from GT11-treated tumors and from THC-treated tumors. Representa-
tive images from each experimental condition are shown. Bar: 20 mm. (E) Effect of THC (15 mg/kg), GT11 (7.5 mg/kg) or THC and GT11 on apoptosis (as determined by
TUNEL). Bars indicate the percentage of TUNEL-positive cells relative to the number of nuclei in each ﬁeld and correspond to 10 ﬁelds of 3 different tumors for each condi-
tion and are expressed as the mean fold change§ s.d. , P < 0.01 from vehicle-treated tumors ##, P < 0.01 from GT11-treated tumors and from THC-treated tumors.
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and enhanced the anticancer activity of this cannabinoid
(Fig. 6A). Analysis of samples derived from these tumors
showed that treatment with GT11 decreased the C16-ceramide:
C16-dihydroceramide ratio (Fig. 6B), and enhanced autophagy
(Fig. 6C), CTSB staining and apoptosis (Fig. 6E) to a similar
extent as THC. Furthermore, the combined administration of
THC and GT11 enhanced CTSB staining and apoptosis in
these tumors (Fig. 6D, Fig. 6E and Fig. S8F). Taken together,
these observations support the notion that pharmacological
manipulation of dihydroceramide levels could be used as a
strategy to stimulate autophagy-mediated cancer cell death in
vivo.
Discussion
To investigate the molecular mechanisms that determine the
outcome (protective or cytotoxic) of autophagy activation, in
this work we compared the effect of 2 autophagic stimuli,
namely nutrient deprivation and THC treatment, which acti-
vate cytoprotective or cytotoxic autophagy in cancer cells,
respectively. Our ﬁndings show that THC, but not nutrient
deprivation, triggers changes in the sphingolipid composition
of the ER (especially an increase in the dihydroceramide:cer-
amide proportion) and that these changes play a crucial role in
the stimulation of autophagy-mediated cancer cell death by
THC. Speciﬁcally, data support the hypothesis that the THC-
promoted modiﬁcation of the sphingolipid composition of
cancer cells is based on its ability to (i) stimulate sphingolipid
synthesis de novo (via enhanced expression of several genes
encoding enzymes of this pathway) and (ii) inhibit the trans-
port of sphingolipids from the ER to the Golgi (at least in part
via inhibition of the ceramide transporter protein COL4A3BP).
In addition, since THC increases the levels of dihydroceramides
to a higher extent than it does with those of ceramides, this
agent might also trigger a partial inhibition of DEGS1 (the
enzyme that catalyzes the conversion of dihydroceramides into
ceramides).28 The precise regulatory mechanisms by which
binding of THC to cannabinoid receptors triggers these
changes in the sphingolipid metabolism of cancer cells have
not been clariﬁed as yet and are currently under investigation
in our laboratories.
In agreement with the notion that autophagosomal mem-
branes are derived, at least in part and under many cellular set-
tings, from the ER,5,33 and that the enzymes involved in the
synthesis of ceramides are located in this organelle, our data
also indicate that changes induced by THC in the sphingolipid
composition of the ER are transmitted to the autophagosomes
during the process that gives origin to the phagophore/omega-
some, and, in turn, to the autolysosome. Local changes in the
concentration of different species of sphingolipids (and speciﬁ-
cally of ceramides) produce membrane permeabilization
through the formation of rigid structures in biological mem-
branes.40,41 Data presented here now show that an increase in
the proportion of dihydroceramides strongly enhances this
effect. Moreover, results obtained using model vesicles reveal
that a local increase in the dihydroceramide:ceramide ratio
(similar to that induced by THC in the microsomal and auto-
phagosome-enriched fraction of U87MG cells) leads to the for-
mation of speciﬁc membrane domains and to increased
permeability of biological membranes. It has been recently
shown that manipulation of the activity of SMPD1 (sphingo-
myelinase phosphodiesterase 1, acid lysosomal; a hydrolytic
enzyme located primarily in the lysosomes) leads to LMP and
stimulation of cancer cell death,36,42 suggesting that changes in
the sphingolipid composition of lysosomes can affect the stabil-
ity of this organelle. Findings presented here now show that
autophagy is required for THC-induced LMP and support the
idea that the fusion of dihydroceramide-enriched autophago-
somes with lysosomes leads in turn to a local increase in the
proportion of dihydroceramides in speciﬁc subdomains of
autolysosomes and lysosomes, thereby leading to membrane
destabilization, LMP and the subsequent release of cathepsins
into the cytoplasm of cancer cells. Of note, ATG7 has been
reported to modulate lysosomal photodamage, through a
mechanism that is unrelated to autophagy.43 In our study we
found that both ATG5- and ATG7-deﬁcient cells were resistant
to THC-induced LMP. However, atg7¡/¡ cells exhibited an
enhanced sensitivity to lysosomal photodamage-induced LMP
(data not shown). These observations are in line with the
notion that autophagy is required for THC-induced LMP and
suggest that lack of ATG7 might affect lysosomal stability in
response to agents acting directly at this organelle.
Our ﬁndings also show that THC-induced autophagy-medi-
ated LMP leads to cell death via stimulation of the mitochon-
drial apoptotic pathway rather than necrotic cell death. It is
worth noting that ceramides had been previously implicated in
autophagy-associated cell death via induction of lethal mitoph-
agy.44 However, we did not ﬁnd a signiﬁcant increase in
mitophagy upon treatment with THC (data not shown) indi-
cating that this mechanism is not responsible for the stimula-
tion of autophagy-mediated cell death in response to treatment
with this cannabinoid. These ﬁndings are in agreement with
previous results from our laboratory showing that autophagy is
upstream of apoptosis in the mechanism of cannabinoid-
induced glioma cell death24 and with the notion that LMP can
activate apoptosis.36,37
Different sphingolipids, and speciﬁcally ceramides, dihy-
droceramides and sphingosine 1-phosphate, have been pro-
posed to regulate autophagy in cancer cells primarily by
acting as upstream triggers of the signaling pathways that
regulate this cellular process.45-51 Likewise, previous obser-
vations from our laboratory have shown that the stimula-
tion of sphingolipid synthesis de novo that triggers THC in
glioma and other types of cancer cells elicits an ER stress-
related pathway that leads to a TRIB3-dependent inhibition
of the AKT-MTORC1 axis and the subsequent activation of
autophagy.24,25 Findings in the present study now support
the notion that the alteration of the sphingolipid metabo-
lism that triggers THC (in addition to activating autophagy
via the abovementioned signaling pathway) leads to modi-
ﬁed sphingolipid content of the ER, autophagosomes and
autolysosomes, and that the latter event plays a crucial role
in determining the cell death-promoting fate of autophagy
stimulation by cannabinoids (Fig. 7). In any case, further
research should clarify whether similar differences in the
sphingolipid composition of these organelles may play a
role in determining the ﬁnal outcome of the stimulation of
the autophagic process in response to other stimuli.
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Of potential relevance in this context, it has been shown that
the selective targeting of mitochondria by MAP1LC3B-II-con-
taining phagophores occurs through direct interaction between
ceramide and MAP1LC3B-II.44 The globular domain of
MAP1LC3B was found to be structurally similar to the cer-
amide-binding domain of COL4A3BP44 (which can also bind
C16-dihydroceramide).52 It is therefore tempting to speculate
that, in addition to regulating membrane stability and the activ-
ity of the above-described ER stress-related signaling pathway,
local changes in the content and subcellular distribution of
C16-dihydroceramide or other dihydrosphingolipids might be
able to modulate autophagy via selective binding to
MAP1LC3B or other autophagy regulatory proteins.
In this report, we also show that treatment with THC or
inhibition of DEGS1 efﬁciently activates autophagy and apo-
ptosis and inhibits tumor growth in mice. These ﬁndings sup-
port the idea that the pharmacological manipulation of the
sphingolipid content (and speciﬁcally of the levels of certain
species of dihydroceramides) may be exploited therapeutically
to promote the activation of autophagy-mediated LMP and
cancer cell death. It is tempting to speculate that this strategy
could be useful to enhance the efﬁcacy of certain anticancer
therapies, for example by turning protective autophagy (that
becomes activated as a mechanism of resistance in response to
treatment with certain antineoplastic agents)12,53 into a cell
death-promoting process.
In summary, ﬁndings presented in this report support
the concept that the stimulation of autophagy-mediated
cancer cell death by THC relies on a modiﬁcation of the
sphingolipid composition of the endoplasmic reticulum of
glioma cells that is transmitted to autophagosomes and
autolysosomes thereby leading to lysosomal membrane per-
meabilization, cathepsin release and the subsequent activa-
tion of apoptotic cell death. We think that these
observations contribute to further support the biological
relevance of sphingolipid metabolites in the regulation of
autophagy and to emphasize the potential therapeutic impli-
cations of modulating the levels of dihydrosphingolipids
such as dihydroceramides for the treatment of cancer.
Materials and methods
Reagents
The following reagents were used: THC (THC Pharm GmbH,
THC-1099), pepstatin A (Enzo Life Sciences, ALX-260-085),
E64d (Enzo Life Sciences, BML-PI107), myriocin (ISP-1,
Sigma-Aldrich, M1177), sphingomyelinase (EC 3.1.4.12) from
Bacillus cereus (Sigma-Aldrich, S7651), o-phenanthroline
(Sigma-Aldrich, 131377) and CA-074 methyl ester (CTSB/
cathepsin B inhibitor; Sigma-Aldrich, C5857). Phosphatidyl-
choline from egg yolk (PC; Lipid Products, grade 1, 840051P),
sphingomyelin, (SM; Avanti Polar Lipids, 860061), C12 cer-
amide (C12-Cer; Avanti Polar Lipids, 860512), C16 dihydrocer-
amide (C16-dhCer; Avanti Polar Lipids, 860634), palmitoyl-
oleoylphosphatidylcholine (POPC; Avanti Polar Lipids,
850457) and cholesterol (Ch; Avanti Polar Lipids, 700000).
DEGS1 inhibitor GT11, and dihydrosphingomyelin (dhSM)
were synthesized in our laboratories. dhSM was synthesized
from egg SM (Avanti Polar Lipids, 860061) and contained 86%
Figure 7. Proposed model of the mechanism by which the intracellular increase of dihydroceramide triggered by THC or by the DEGS inhibitor GT11 promotes glioma cell
death. THC binding to CNR1 (cannabinoid receptor 1 [brain]) and CNR2 (cannabinoid receptor 2) stimulates de novo synthesis of ceramide and inhibits the transport of
ceramide from the ER to the Golgi inducing a modiﬁcation on the ER sphingolipid composition. This event triggers: (i) the induction of an ER stress response that leads to
a TRIB3-dependent inhibition of the AKT-MTORC1 axis and the subsequent induction of autophagy and (ii) a modiﬁcation of the ceramide to dihydroceramide (Cer:dhCer)
ratio in the ER. The DEGS1 inhibitor GT11 produces a similar decrease on the ratio Cer:dhCer. The alteration in the Cer:dhCer ratio triggered by THC or GT11 is transmitted
to autophagosomes and autolysosomes, thus modifying the permeability of the membranes, facilitating LMP, cathepsin release and the subsequent activation of apopto-
sis and cell death.
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C16 dhSM. ANTS (Molecular Probes, Inc., A350), DPX
(Molecular Probes, Inc., X1525) and DiIC18 (Molecular Probes,
D3911). BODIPY FL C5-ceramide complexed to BSA (Ther-
moFisher Scientiﬁc, B22650).
Cell culture
U87MG (human glioma cell line), A375 and SK-MEL28 cells
were obtained from the American Type Culture Collection
(Rockville, MD, USA; ATCC HTB-14TM, ATCC CRL-
1619TM, ATCC HTB-72TM). T-Large antigen-Atg5C/C and
atg5¡/¡ MEFs were transformed using a retroviral vector
expressing a mutated (Gly12Val) and constitutively active form
of HRAS (Harvey rat sarcoma virus oncogene) (HRASG12V;
HRASV12/T-large-MEFs) as previously described.54 Trans-
formed/stably transfected MEFs correspond to a polyclonal
mix of at least 20 different selected clones. Cells were cultured
in DMEM (Lonza, BE-12-604F) containing 10% fetal bovine
serum (FBS; Linus, 91S1800) and penicillin/ streptomycin
(5 mg/ml; Lonza, BE17-603E). When required, cells were
seeded at a density of 5000–10,000 cells/cm2 and transferred to
medium containing 0.5% FBS, 18 h before performing the dif-
ferent treatments. For nutrient deprivation experiments, cells
were incubated in Earles balanced salt solution (EBSS) medium
(Lonza, BE10-502F). T-large antigen-immortalized Atg5C/C,
atg5¡/¡, Atg7C/C and atg7¡/¡ MEFs were kindly provided by
Noboru Mizushima (The University of Tokyo, Japan)
Infection with ATG5 shRNA-human lentiviral particles
A pool of concentrated transduction-ready viral particles con-
taining 3 shRNAs target-speciﬁc (or 3 shRNA nontargeted con-
trol) constructs (19–25 nucleotide plus hairpin; Santa Cruz
Biotechnology, sc-41445-V) was used to stably knock down the
expression of ATG5 in U87MG cells. Brieﬂy, cells were plated
in 12-well dishes 24 h prior to viral infection. The day after,
when the cells reached 50% conﬂuence, medium was removed
and replaced by complete medium with hexadimethrine bro-
mide (Sigma- Aldrich, H9268-5G) at a ﬁnal concentration of
5 mg/ml. Cells were subsequently infected with control- or
ATG5-selective shRNA lentiviral particles. The day after, the
medium was removed and replaced by complete medium with-
out hexadimethrine bromide. Finally, to select the clones stably
expressing the shRNAs, the cells were incubated with puromy-
cin (Gibco, 10296974) at a concentration of 2 to 10 mg/ml.
Finally, clones were selected and stable silencing was conﬁrmed
by different approaches. At least 20 different selected clones
were pooled for each of the cell lines generated.
Real-time quantitative PCR
RNA was isolated by using Trizol Reagent (Sigma- Aldrich,
T9424) following the manufacturers instructions and including
a DNase digestion step with the RNasefree DNase kit (Qiagen,
79254). cDNA was subsequently obtained using the Transcrip-
tor ﬁrst strand cDNA synthesis kit (Roche, 04897030001).
Real-time quantitative PCR assays were performed using the
FastStart Master Mix with Rox (Roche, 04914058001) and
probes were obtained from the Universal Probe Library Set
(Roche). The following primer sequences and Roches probes
were used for detecting human CERS2 transcript variant 1
(Forward 5-GACGGAGTACACGGAGCAG-3, Reverse 5-CGT
TCCCACCAGAAGTAATCA- 30 probe 50), human CERS5
(Forward 5-GCCATCCTTGAAAAGGTGTT-3, Reverse 5-AA
TCCAGCTGCTTTGACAGG-3, probe 19), human CERS6
(Forward 5-TCATGATTCAGCTGATGCTCTT-3, Reverse 5-
CACATTTTCTGAAACTTGGCATA-3 probe 75), human
DEGS1 (Forward 5-GGAAGACTTCGAGTGGGTCTAC-3,
Reverse 5- TTCATCAAGGACTTTATCTCTGGA-3, probe
28), human SPTLC1 (Forward 5-CATTAACTCAGGCGCCG-
TAC-3, Reverse 5-GTTCCACCGTGACCACAAC-3, probe
52). Ampliﬁcations were run in a 7900 HT-Fast Real-Time
PCR System (Applied Biosystems; California, USA). Each value
was adjusted by using RNA18S1 levels as reference (Forward 5-
GCTCTAGAATTACCACAGTTATCCAA-3, Reverse 5-AAA
TCAGTTATGGTTCCTTTGGTC-3, probe 55).
Transfections of expression vectors
Transfections of expression vectors were performed with Lipo-
fectamine 2000 (Invitrogen, 11668019) according to the man-
ufacturers instructions. Plasmids pEGFP-COL4A3BP and the
mutant pEGFP-COL4A3BP S132A have been previously
described.31 The plasmid encoding ZFYVE1/DFCP1-MYC and
WIPI1-HA were kindly provided by Dr Nicholas Ktistakis
(Babraham Institute, Cambridge, UK) and Dr. Sharon A. Tooze
(The Francis Crick Institute, London, UK), respectively.
Cell viability assays
Cell viability was determined by the MTT ((3-[4,5-dimethylth-
iazol-2-yl]-2,5-diphenyltetrazolium bromide, a yellow tetra-
zole) (Sigma-Aldrich, M2128) test following the manufacturers
instructions. Absorbance at 570 nm, which is proportional to
the amount of viable cells in the culture, was quantiﬁed using a
spectrophotometer.
Cell lysates
Cells were lysed in a buffer containing 50 mM Tris HCl (Roth,
20485000), pH 7.5, 1 mM phenylmethylsulfonyl ﬂuoride,
50 mM NaF, 5 mM sodium pyrophosphate, 1 mM sodium
orthovanadate, 0.1% Triton X-100, 1 mg/ml leupeptin, 1 mM
EDTA, 1 mM EGTA and 10 mM sodium b-glycerophosphate
(Sigma-Aldrich, 329-98-6, S7920, T6379, S6508, L8511, ED,
E4378, G6251, T9284, respetively).
Western blot
Western blot analysis was performed following standard proce-
dures.55 Primary antibodies raised against NFKBIA (1:2000;
Santa Cruz Biotechnology, sc-371), ACTB, TUBA1A,
MAP1LC3B, TGOLN2 (1:5000, 1:5000, 1:3000, 1:1000; Sigma-
Aldrich, A5441, T9026, L7543, T7576), LAMP2, EEA1 (1:1000,
1:500; BD Biosciences 555803 and 610457), COL4A3BP
(1:1000; Bethyl, A300-669A), CANX (1:500; StressMarq, SPC-
108B), GOLGA2 (1:1000; Abcam, ab52649), and LAMP1
(1:1000; Abcam, ab24170), were used. Densitometric analysis
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was performed with Quantity One software (Bio-Rad; Califor-
nia, USA).
Lipid extraction
Brieﬂy, 1 to 10 £ 106 pelleted U87MG cells were mixed with
0.5 ml methanol (Merck, 1.06018.1000) and 0.25 ml chloro-
form (Scharlab, CL01981000) and internal standards were
added (200 pmol C12-Cer, SM, and GlcCer; Avanti Polar Lip-
ids, 860512, 860583, 860543). Samples were heated at 48C
overnight. The next day, 75 ml 1 M KOH (Panreac,
141515.1211) in methanol were added, followed by 2-h incuba-
tion at 37C. Finally, the mixtures were neutralized with 75 ml
1 M acetic acid (Panreac, 161008.1611), and dried under
nitrogen.
Lipidomics
Lipid extracts were solubilized in 150 ml methanol. The liquid
chromatography-mass spectrometer consisted of a Waters
Aquity UPLC system connected to a Waters LCT Premier
Orthogonal Accelerated Time of Flight Mass Spectrometer
(Waters, Millford, MA, USA), operated in positive or negative
electrospray ionization mode. Full scan spectra from 50 to 1500
Da were obtained. Mass accuracy and reproducibility were
maintained by using an independent reference spray via Lock-
Spray. A 100 mm £ 2.1 mm id, 1.7 mm C8 Acquity UPLC
BEH (Waters) analytical column was used. The 2 mobile phases
were 1 mM ammonium formate (Fluka, 09735) in methanol
(phase A) and 2 mM ammonium formate in H2O (Fisher Sci-
entiﬁc, W6-212) (phase B), both phases with 0.05 mM formic
acid (Merck, 1.00264.1000). Two gradients were programmed:
gradient I: 0 min, 80% A; 3 min, 90% A; 6 min, 90% A; 15 min,
99% A; 18 min, 99% A; 20 min, 80% A and gradient II: 0 min,
65% A; 2 min, 65% A; 5 min, 90% A; 11 min, 99% A; 12 min,
99% A; 14 min, 65% A. In both cases, the ﬂow rate was 0.3 ml/
min. The column was run at 30C. Quantiﬁcation was carried
out using the ion chromatogram obtained for each compound
using 50-mDa windows. The linear dynamic range was deter-
mined by injection of standard mixtures. Positive identiﬁcation
of compounds was based on the accurate mass measurement
with an error <5 ppm and its LC retention time, compared to
that of a standard (§ 2%). Sphingolipids were annotated as
hlipid subclassihtotal fatty acyl chain lengthi:htotal number
of unsaturated bondsi. If the sphingoid base residue was
dihydrosphingosine the lipid class contained a hDHi preﬁx.
Confocal laser scanning microscopy
Standard protocols for immunoﬂuorescence microscopy were
used. Brieﬂy, cell cultures grown on 12-mm coverslips (Menzel
Gl€asser, P231.2) were washed in phosphate-buffered saline
(PBS; 137 mM NaCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4,
pH 7.5), ﬁxed with 4% paraformaldehyde (Sigma-Aldrich,
P6148) (20 min at room temperature) and permeabilized with
0.5% Triton X-100 (5 min at room temperature). Cells were
then incubated with the corresponding primary antibodies
diluted in PBS containing 0.1% w/v BSA (Sigma-Aldrich,
A6003) for 2 h and washed 3 times with this same buffer.
Incubation with the appropriate Alexa Fluor 488- or Alexa
Fluor 594-conjugated secondary antibodies (1:1000, Invitrogen,
A-11008, A-11005, A-11001, R37117) was performed in the
dark at room temperature for 90 min. Cell nuclei were stained
with DAPI (Roche, 010236276001; 10 min, room temperature).
Finally, coverslips were mounted in Mowiol mounting medium
(Calbiochem, 475704) and observed in a Leica TCS SP2 confo-
cal microscope. At least 200 cells per condition were counted in
randomly selected ﬁelds and the results represent the mean
value § STDEV corresponding to the randomly selected ﬁelds
of a representative experiment. Primary antibodies were as
described above and additionally included anti-HA (16B12
clone; Covance MMS-101P), CTSB (EMD Millipore, IM27L),
anti-MYC (9E10 clone; Roche, 11667203001), and PDIA/PDI
(Abcam, ab3672). In the double immunostaining with LAMP2
and CTSB antibodies, the mouse-on-mouse blocking reagent
(Vector Labs, MKB2213) was used.
Electron microscopy
U87MG cell were chemically ﬁxed at 4C with a mixture of 2%
paraformaldehyde and 0.1% glutaraldehyde (Sigma-Aldrich,
340855) in PBS buffer. After washing with PBS containing
50 mM glycine (Sigma-Aldrich, G7126), cells were embedded
in 12% gelatin (Sigma-Aldrich, G1393) and infused in 2.3 M
sucrose ((Roth, 4261.1). Mounted gelatine blocks were frozen
in liquid nitrogen. Thin sections were prepared in an ultracryo-
microtome (Leica EM Ultracut UC6/FC6, Vienna, Austria).
Ultrathin cryosections were collected with 2% methylcellulose
in 2.3 M sucrose (Roth, 4261.1). Cryosections were incubated
at room temperature on drops of 2% gelatin in PBS for 20 min
at 37C, followed by 50 mM glycine in PBS for 15 min and 10%
FBS in PBS for 10 min, and ﬁnally 5% FBS in PBS for 5 min.
Cryosections were subsequently incubated with anti-
COL4A3BP (Bethyl, A300-669A) in 5% FBS in PBS for 30 min.
After 3 washes with drops of PBS for 10 min, sections were
incubated for 20 min using IgG anti-mouse coupled to 10-nm
diameter colloidal gold particles (Electron Microscopy Sciences,
25108) using a (1:200) dilution in 5% FBS in PBS. This was fol-
lowed by 3 washes with drops of PBS for 10 min, and 2 washes
with distilled water. As a control for non speciﬁc binding of the
colloidal gold-conjugated antibody, the primary antibody was
omitted. Preparations were observed in an Electron Microscope
Tecnai Spirit (FEI Company, The Netherlands) with a CCD
camera SIS Megaview III or in a Jeol J1010 (Jeol, Japan) with a
CCD camera SIS Megaview III.
Isolation of the autophagosomal-enriched fraction
U87MG cells were cultured in 150-mm dishes at 10,000 cells/
cm2 and starved in EBSS medium or treated with THC during
6 h. Then, cells were harvested with a scraper, collected in tubes
and centrifuged at 800 x g, at room temperature for 5 min. The
package cellular volume (PCV) of the pellet fractions was mea-
sured, and each pellet was suspended in 3 volumes of the PCV
in hypotonic buffer, incubated for 20 min at 4C and centri-
fuged at 600 x g for 5 min. The new PCV was suspended in 2
volumes of isotonic buffer and homogenized with a Potter Elve-
jem homogenizer. The microsomal fraction was prepared with
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3 sequential centrifugations (1,000 x g, 4C, 5 min; 12,000 x g,
4C, 15 min; and 100,000 x g, 4C, 2 h). Next, the pellet fraction
was suspended in 0.8 ml 0.25 M sucrose and 1.4 ml of Opti-
PrepTM (Progen Biotechnik, 11145429), and was placed at the
bottom of Ultra-ClearTM Tubes (14£95 mm; Beckman–Coul-
ter, 82355618). A discontinuous OptiPrepTM gradient was
constructed by modiﬁcation of the method described by Mar-
zella et al.56 The layers from the bottom to the top were: 3 ml of
26% OptiPrepTM, 2 ml of 24% OptiPrepTM, 2 ml of 20% Opti-
PrepTM and 2 ml of 15% OptiPrepTM. After centrifugation at
90,017 x g for 3 h at 4C in an SW40Ti rotor (Beckman Instru-
ments, Spinco Div., Palo Alto, CA), fractions of 0.5 ml were col-
lected and analyzed.
Liposome preparation
LUVs of diameters 100–150 nm were prepared by the extrusion
method using a LIPEX Liposome Extrusion System (Transferra
Nanosciences, Burnaby, Canada) equipped with nuclepore ﬁl-
ters of 0.1-mm pore diameter (Whatman, 110605), at 65C in
10 mM HEPES (Sigma-Aldrich, H7006), 150 mM NaCl,
10 mM CaCl2, 2 mM MgCl2, pH 7. The ﬁnal lipid concentra-
tion was 2 mM. GUVs were prepared following the electrofor-
mation method described previously,57 using a homemade
chamber (Industrias Tecnicas ITC, Bizcaya, Spain) that allows
direct visualization under the microscope. Stock solutions of
lipids (0.2 mg/ml total lipid containing 0.4 mol DiC18) were
prepared in chloroform:methanol (2:1, v/v) solution. 3 mL of
the appropriate stocks were added onto the surface of platinum
electrodes, and solvent traces were removed under vacuum for
at least 2 h. The platinum electrodes were covered with 400 ml
of 25 mM HEPES, 150 mM NaCl, pH 7.5 buffer previously
heated at 65C, and connected to an electric wave generator
(TG330 function generator, Thurlby Thandar Instruments,
Huntington, UK) under AC ﬁeld conditions (1] 500 Hz, 0.08 V
for 6 min; 2] 500 Hz, 1.0 V for 20 min; 3] 500 Hz, 3.0 V for 1 h
30 min) at 65C. Phospholipid concentration was measured in
terms of lipid phosphorus.58
Fluorescence microscopy
Giant vesicles were visualized in an inverted confocal ﬂuores-
cence microscope with a high-efﬁciency spectral detector (Leica
TCS SP5; Leica Microsystems CMS GmbH, Mannheim,
Germany). The excitation wavelength was 514 nm, and the
ﬂuorescence signal was collected in the 570–610 nm channel.
Images were collected and analyzed with the LAS AF software
(Leica Microsystems).
Release of vesicle contents was assayed with the ANTS:
DPX ﬂuorescence system
Details on the use of these ﬂuorescent probes, including assay
calibration, have been given elsewhere.59,60 Leakage was fol-
lowed in terms of ANTS ﬂuorescence at 37C in a
QuantaMasterTM spectroﬂuorometer series (Photon Technol-
ogy International, Birmingham, NJ, USA). Since commercial
sphingomyelinase preparations may contain phospholipase C
impurities, 2 mM o-phenanthroline (Sigma-Aldrich, 131377)
was routinely added in all our enzyme assays. The lipid concen-
tration was 0.3 mM and sphingomyelinase was used at 0.15
units/ml.
Cathepsin activity measurements
A total of 15,000 cells/well were plated and cultured in 12-well
plates 1 d prior to THC treatment. Three hundred ml of extrac-
tion buffer (250 mM sucrose, 20 mM HEPES, 10 mM KCl
[Sigma- Aldrich, P9333], 1.5 mM MgCl2, 1 mM EGTA, 1 mM
EDTA, 8 mM DTT [Sigma-Aldrich, D0632], 1 mM Pefabloc
SC [Sigma-Aldrich, 30827-99-7], pH 7.5) with either 13 mg/ml
(for the cytosolic fraction) or 200 mg/ml (for total protein) of
digitonin (Sigma-Aldrich, D141) was added to the cells. After a
12-min incubation at 4C, 250 ml of the supernatant fraction
was transferred to a microtiter plate. Fifty ml of extract per sam-
ple were transferred to black Costar 96-well plates into 50 ml of
2x cathepsin reaction buffer (50 mM sodium acetate, 8 mM
EDTA, 8 mM DTT, 1 mM Pefabloc SC, pH 5.0) containing
the zFR-AFC (50 mM; Enzo, ALX-260-129-M005) cathepsin
substrate. To measure cysteine cathepsin activity, plates were
prewarmed for 5 min at 30C and light emission (max.
489 nm, cutoff at 475 nm; excitation at 400 nm) was measured
on a SpectraMax Gemini ﬂuorescent reader (Molecular Devi-
ces, Sunnyvale, CA, USA) every 2 min for 30 min.
CTSB and CYCS release detection
U87MG cells cultured on P100 plates (TPP, 93100) were lysed
in plasma membrane permeabilization buffer (50 ug/ml digito-
nin, 80 mM KCl in PBS), 16 h after the corresponding treat-
ments, and the presence of CYCS or CTSB in the cytosolic
fraction were analyzed as previously described.61
In vivo treatments
Tumors derived from U87MG cells were induced in Hsd:Athy-
micNude-Foxn1nu mice (Envigo RMS-Spain) by subcutaneous
injection of 9 £ 106 cells in PBS supplemented with 0.1% glu-
cose. Tumors were allowed to grow until an average volume of
250–300 mm3 and animals were assigned randomly to the dif-
ferent groups. Treatments were administered with a single peri-
tumoral (local) injection, in 100 ml of PBS supplemented with
5 mg/ml BSA. Tumors were measured with external caliper,
and volume was calculated as (4p/3) x (width/2)2 x (length/2).
All procedures involving animals were performed with the
approval of the Complutense University Animal Experimenta-
tion Committee according to Spanish and European ofﬁcial
regulations.
Immunomicroscopy of tumor samples
Samples from tumor xenografts were dissected, OCT Tissue-
Tek (SAKURA FINETEK, E11K4583) embedded and frozen.
Standard protocols for immunoﬂuorescence microscopy were
used.
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Tunel
Tumor samples were ﬁxed, blocked and permeabilized and
TUNEL was performed as previously described.22
Statistics
Statistical analyses were performed by ANOVA with a post hoc
analysis by the Student-Neuman-Keuls test.
Abbreviations
ACTB actin, b
ATG autophagy related
Cer ceramide
COL4A3BP/CERT collagen, type IV, a 3 (Goodpasture anti-
gen) binding protein
CTSB cathepsin B
CYCS cytochrome c, somatic
DEGS1 delta(4)-desaturase, sphingolipid 1
dhCer dihydroceramide
EBSS Earle’s balanced salt solution
ER endoplasmic reticulum
GUVs giant unilamellar vesicles
LMP lysosomal membrane permeabilization
LUV large unilamellar vesicles
MAP1LC3/LC3 microtubule-associated protein 1 light
chain 3
MEFs mouse embryonic ﬁbroblasts
MTORC1 mechanistic target of rapamycin (serine/
threonine kinase) complex 1
PCV package cellular volume
THC D9-tetrahydrocannabinol
TRIB3 tribbles pseudokinase 3
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